📰 Recursion Pharmaceuticals Trading News
Recursion Pharmaceuticals Trading News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Recursion Pharmaceuticals Trading. Real-time updates on events, politics, business and more.
June 4, 2024
Lingotto Investment Management LLP lifted its position in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX – Free Report) by 141.9% during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 1,875,077 shares of the company’s stock after buying an additional 1,100,000 shares during the period. Recursion […]
October 4, 2023
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX – Get Free Report) COO Tina Marriott Larson sold 3,000 shares of the firm’s stock in a transaction on Thursday, September 28th. The shares were sold at an average price of $7.72, for a total value of $23,160.00. Following the completion of the sale, the chief operating officer now owns 418,782 […]
August 28, 2023
Platinum Investment Management Ltd. grew its position in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX – Free Report) by 2.2% in the 1st quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 2,770,451 shares of the company’s stock after buying an additional 60,112 shares during the period. Platinum Investment Management Ltd.’s […]
August 18, 2023
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX – Get Free Report) insider Shafique Virani sold 18,000 shares of the stock in a transaction that occurred on Tuesday, August 15th. The shares were sold at an average price of $9.25, for a total transaction of $166,500.00. Following the completion of the sale, the insider now directly owns 140,351 shares […]
July 25, 2023
Nikko Asset Management Americas Inc. boosted its holdings in shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX – Free Report) by 10.4% in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 501,977 shares of the company’s stock after buying an additional 47,455 shares during the […]
June 7, 2023
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX – Get Rating)’s stock price gapped up prior to trading on Wednesday . The stock had previously closed at $8.63, but opened at $9.00. Recursion Pharmaceuticals shares last traded at $9.18, with a volume of 293,828 shares changing hands. Wall Street Analysts Forecast Growth RXRX has been the topic of a […]
May 6, 2023
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX – Get Rating) CEO Christopher Gibson sold 33,073 shares of the firm’s stock in a transaction dated Wednesday, May 3rd. The stock was sold at an average price of $4.71, for a total transaction of $155,773.83. Following the sale, the chief executive officer now directly owns 953,225 shares in the company, […]
April 23, 2023
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX – Get Rating) Director Blake Borgeson sold 8,885 shares of the firm’s stock in a transaction dated Tuesday, April 18th. The shares were sold at an average price of $5.93, for a total transaction of $52,688.05. Following the transaction, the director now directly owns 7,558,517 shares in the company, valued at […]